Author(s)

Fiona Gonon

Affiliation(s)

University of Manchester, Manchester, UK.

Corresponding Author

Fiona Gonon

ABSTRACT

Alzheimer's disease (AD) is a common degenerative disease of the central nervous system, and early diagnosis is very important for its treatment. However, clinical diagnosis currently requires invasive lumbar puncture or expensive Aβ/Tau PET examination, resulting in a lag in early diagnosis. Peripheral blood has the advantages of being non-invasive, easy to obtain, and suitable for disease tracking and follow-up. Over the years, research has been striving to find early specific biomarkers of AD in peripheral blood. However, due to the low concentration of brain-derived proteins in blood and their vulnerability to interference from plasma matrix proteins, previous studies using traditional enzyme-linked immunosorbent assay (ELISA) to detect AD-related proteins in blood have been inconsistent. In recent years, some ultra-sensitive detection technologies have been gradually applied to the study of AD blood protein markers. The relevant results show that Aβ, p-Tau and exosomes in blood have potential application value in the early diagnosis, identification and prediction of AD. Therefore, this article reviews the research progress of AD protein markers in blood in the past five years to improve the understanding of blood biomarkers in the diagnosis and treatment of AD and provide guidance for their better early clinical application.

KEYWORDS

Alzheimer's disease; Blood biomarkers; Ultra-sensitive detection technology

CITE THIS PAPER

Fiona Gonon. Study on blood protein markers of Alzheimer's disease. World Journal of Biomedical Sciences. 2024, 2(1): 23-28. DOI: 10.61784/wjbs240145.

REFERENCES

[1] Frisoni GB, Winblad B, O′Brien JT. Revised NIA-AA criteria for the diagnosis of Alzheimer,s disease: a step forward but not yet ready for widespread clinical use. Int Psychogeriatr, 2011, 23 (8): 1191 1196.

[2] Jack CR, Bennett DA, Blennow K. NIA-AA Research Framework: toward a biological definition of Alzheimer, s disease. Alzheimers Dement, 2018, 14  (4): 535 -562.

[3] Verberk IM, Slot RE, Verfaillie SC. Plasma amyloid as prescreener for the earliest Alzheimer pathological changes. Ann Neurol, 2018, 84 (5): 648 -658.

[4] Blasko I, Jellinger K, Kemmler G. Conversion from cognitive health to mild cognitive impairment and Alzheimer,s disease: prediction by plasma amyloid beta42, medial temporal lobe atrophy and homocysteine. Neurobiol Aging, 2008, 29 (1): 1 11.

[5] Mayeux R, Honig LS, Tang MX. Plasma Abeta40 and Abeta42 and Alzheimer,s disease: relation to age, mortality, and risk. Neurology, 2003, 61 (9):  1185 1190.

[6] Hansson O, Zetterberg H, Vanmechelen E. Evaluation of plasma Abeta (40) and Abeta (42) as predictors of conversion to Alzheimer, s disease in patients with mild cognitive impairment. Neurobiol Aging,  2010, 31 (3): 357 -367.

[7] Lopez OL, Kuller LH, Mehta PD. Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology, 2008, 70  (19): 1664 1671.

[8] Lewczuk P, Kornhuber J, Vanmechelen E. Amyloid beta peptides in plasma in early diagnosis of Alzheimer,s disease: A multicenter study with multiplexing. Exp Neurol, 2010, 223 (2): 366 -370.

[9] Fukumoto H, Tennis M, Locascio JJ. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol, 2003, 60 (7):  958 -964.

[10] Zetterberg H. Blood-based biomarkers for Alzheimer,s disease-An update. J Neurosci Methods, 2019,  319: 2 -6.

[11] Landau SM, Mintun MA, Joshi AD. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol, 2012, 72 (4): 578-586.

[12] Snyder HM, Carrillo MC, Grodstein F. Developing novel blood-based biomarkers for Alzheimer,s disease. Alzheimers Dement, 2014,  10 (1): 109 114.

[13] Janelidze S, Stomrud E, Palmqvist S. Plasma β-amyloid in Alzheimer,s disease and vascular disease. Sci Rep, 2016, 6: 26801.

[14] Startin CM, Ashton NJ, Hamburg S. Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer, s disease. Alzheimers Res Ther, 2019, 11 (1): 26.

[15] Jiao F, Yi F, Wang Y. The validation of multifactor model of plasma Aβ42 and total-Tau in combination with MoCA for diagnosing probable Alzheimer disease. Front Aging Neurosci, 2020, 12: 212.

[16] Lue LF, Sabbagh MN, Chiu MJ. Plasma levels of Aβ42 and Tau identified probable Alzheimer, s dementia: Findings in two cohorts. Front Aging Neurosci, 2017, 9: 226.

[17] Yang SY, Chiu MJ, Chen TF. Detection of plasma biomarkers using immunomagnetic reduction: A promising method for the early diagnosis of Alzheimer, s disease. Neurol Ther, 2017, 6 (Suppl 1):  37 -56.

[18] Teunissen CE, Chiu MJ, Yang CC. Plasma amyloidβ (Aβ42 )  correlates with cerebrospinal fluid Aβ42 in Alzheimer, s disease. J Alzheimers Dis,  2018, 62 (4): 1857 1863.

[19] Chiu MJ, Chen TF, Hu CJ. Nanoparticle-based immunomagnetic assay of plasma biomarkers for differentiating dementia and prodromal states of Alzheimer, s disease A cross-validation study. Nanomedicine, 2020, 28: 102182.

[20] Koychev I, Jansen K, Dette A. Blood-based ATN biomarkers of Alzheimer,s disease: A meta-analysis. J Alzheimers Dis, 2021, 79 (1): 177 195.

[21] Meyer S de, Schaeverbeke JM, Verberk IM. Comparison of ELISAand SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis. Alzheimers Res Ther,  2020,  12  (1): 162.

[22] Lin SY, Lin KJ, Lin PC. Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer,s disease. Alzheimers Res Ther, 2019, 11 (1): 111.

[23] Keshavan A, Pannee J, Karikari TK. Population-based blood screening for preclinical Alzheimer,s disease in a British birth cohort at age 70. Brain,  2021, 144 (2): 434 -449.

[24] Ovod V, Ramsey KN, Mawuenyega KG. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement, 2017, 13 (8):  841 -849.

[25] Kaneko N, Nakamura A, Washimi Y. Novel plasma biomarkersurrogating cerebral amyloid deposition. Proc Jpn Acad, Ser B, Phys Biol Sci, 2014,  90 (9): 353 -364.

[26] Nakamura A, Kaneko N, Villemagne VL. High performance plasma amyloidβ biomarkers for Alzheimer,s disease. Nature, 2018, 554 (7691): 249 -254.

[27] Snitz BE, Wang T, Cloonan YK. Risk of progression from subjective cognitive decline to mild cognitive impairment: The role of study setting. Alzheimers Dement, 2018, 14 (6): 734 -742.

[28] Chen TB, Lee YJ, Lin SY. Plasma Aβ42 and total tau predict cognitive decline in amnestic mild cognitive impairment. Sci Rep, 2019, 9 (1): 13984.

[29] Dage JL, Wennberg AM, Airey DC. Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort. Alzheimers Dement,  2016,  12  (12): 1226 1234.

[30] Mattsson N, Zetterberg H, Janelidze S. Plasma tau in Alzheimer disease. Neurology, 2016, 87 (17): 1827 1835.

[31] Fossati S, Ramos Cejudo J, Debure L. Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer, s disease. Alzheimers Dement  (Amst), 2019, 11: 483 -492.

[32] Yang SY, Chiu MJ, Chen TF. Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases. Sci Rep, 2017, 7 (1): 9304.

[33] Ashton NJ, Pascoal TA, Karikari TK. Plasma p-tau231: a new biomarker for incipient Alzheimer,s disease pathology. Acta Neuropathol, 2021, 141  (5): 709 -724.

[34] Suárez-Calvet M, Karikari TK, Ashton NJ. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer,s continuum when only subtle changes in Aβ pathology are detected. EMBO Mol Med, 2020, 12  (12): e12921.

[35] Yang CC, Chiu MJ, Chen TF. Assay of plasma phosphorylated tau protein (Threonine 181) and total tau protein in early-stage Alzheimer, s disease. J Alzheimers Dis, 2018, 61 (4): 1323 1332.

[36] Janelidze S, Mattsson N, Palmqvist S. Plasma P-tau181 in Alzheimer,s disease: relationship to other biomarkers,  differential diagnosis,  neuropathology and longitudinal progression to Alzheimer,s dementia. Nat Med, 2020, 26 (3): 379 -386.

[37] Karikari TK, Pascoal TA, Ashton NJ. Blood phosphorylated tau181 as a biomarker for Alzheimer,s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol, 2020, 19 (5): 422 -433.

[38] Benussi A, Karikari TK, Ashton N. Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry, 2020, 91 (9): 960 -967.

[39] Thijssen EH, La Joie R, Wolf A. Diagnostic value of plasma phosphorylated tau181 in Alzheimer,s disease and frontotemporal lobar degeneration. Nat Med, 2020, 26 (3): 387 -397.

[40] Palmqvist S, Janelidze S, Quiroz YT. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative Disorders. JAMA, 2020, 324 (8): 772 -781.